Castle Biosciences specializes in developing and commercializing diagnostic and prognostic tests for dermatologic cancers. The company focuses on creating novel, clinically actionable, tumor-specific genomic tests that aid in improved decision-making and patient care. Their primary clients include healthcare providers and dermatologists who require precise genomic information to make more accurate treatment plans for conditions such as cutaneous and uveal melanoma. Operating in the healthcare and biotechnology market, Castle Biosciences generates revenue by selling their proprietary gene expression profile (GEP) tests. These tests provide personalized, actionable genomic data that help clinicians tailor treatment plans to individual patients, thereby improving outcomes. The company’s business model revolves around continuous innovation in genomic testing and expanding their portfolio to address unmet clinical needs in dermatologic oncology.

Keywords: genomic tests, dermatologic cancers, prognostic, diagnostic, melanoma, healthcare providers, biotechnology, personalized medicine, gene expression profile, patient care.